GLP-1 Users Report Delayed Colon Cancer Diagnoses as Symptoms Overlap, Survival Drops to 13% After Spread
Updated
Updated · New York Post · May 11
GLP-1 Users Report Delayed Colon Cancer Diagnoses as Symptoms Overlap, Survival Drops to 13% After Spread
5 articles · Updated · New York Post · May 11
Two patient accounts detailed how Ozempic and Mounjaro side effects appeared to mirror early colorectal cancer symptoms, delaying care until one woman was diagnosed at stage 2 and another at stage 4.
Doctors say GLP-1 drugs commonly cause constipation, bloating and abdominal discomfort—the same complaints seen in colorectal cancer—making fatigue, bowel changes and weight loss easy to misread.
Brooke Hinderhan, 47, canceled a colonoscopy after symptoms worsened, then learned in the ER that a baseball-sized colon tumor was nearly blocking her bowel; surgery later found no lymph-node spread.
Michelle Lyson, 55, said years of gastrointestinal problems were repeatedly attributed to Ozempic before blood in her stool and a positive Cologuard led to a diagnosis that had already spread to her peritoneum.
More than 90% of colorectal cancer patients survive at least five years when caught early, but that falls to about 13% after spread; specialists say rectal bleeding and narrowed stool are not normal GLP-1 effects.
When GLP-1 side effects mask cancer, who is responsible: doctors, drug makers, or patients?
Could popular weight-loss drugs be preventing more cancers than they are masking?
GLP-1 Drugs Linked to Dramatic Drop in Colon Cancer Deaths—But May Delay Diagnosis by Masking Early Symptoms
Overview
GLP-1 medications, widely used for diabetes and weight loss, can mask early symptoms of colon cancer because their common gastrointestinal side effects—like changes in bowel habits and abdominal discomfort—overlap with warning signs of cancer. This overlap often leads patients and healthcare providers to attribute these symptoms solely to the medication, causing delays in further investigation and diagnosis. As a result, colon cancer may be detected late, leading to poorer outcomes. Real patient experiences highlight this risk, emphasizing the urgent need for greater awareness and vigilance to ensure timely detection and treatment.